- Home
- VXRT
VXRT
Vaxart Inc
as 12-20-2024 3:44pm EST
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 200.3M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $1.54 | Next Earning Date: | 11-13-2024 |
| Revenue: | $16,760,000 | Revenue Growth: | 303.27% |
| Revenue Growth (this year): | 128.43% | Revenue Growth (next year): | -31.32% |
Latest Vaxart Inc News
VXRT Breaking Stock News: Dive into VXRT Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
Vaxart Completes Sentinel Cohort Enrollment in Phase 2b COVID-19 Vaccine Trial
GlobeNewswire
19 days ago
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
GlobeNewswire
a month ago
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Vaxart Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
a month ago
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...
Zacks
a month ago
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13
Compare VXRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VXRT Vaxart Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.